SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-356359"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-356359" > International Exper...

International Expert Consensus on Switching Platelet P2Y(12) Receptor-Inhibiting Therapies

Angiolillo, Dominick J. (författare)
Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA.
Rollini, Fabiana (författare)
Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA.
Storey, Robert F. (författare)
Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England.
visa fler...
Bhatt, Deepak L. (författare)
Brigham & Womens Hosp, Harvard Med Sch, Heart & Vasc Ctr, Boston, MA USA.
James, Stefan K, 1964- (författare)
Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
Schneider, David J. (författare)
Univ Vermont, Cardiovasc Res Inst, Cardiol Unit, Dept Med, Burlington, VT 05405 USA.
Sibbing, Dirk (författare)
Ludwig Maximilians Univ Munchen, Dept Cardiol, Munich, Germany.;DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Berlin, Germany.
So, Derek Y. F. (författare)
Univ Ottawa, Heart Inst, Div Cardiol, Ottawa, ON, Canada.
Trenk, Dietmar (författare)
Univ Heart Ctr Freiburg Bad Krozingen, Dept Cardiol & Angiol 2, Freiberg, Germany.
Alexopoulos, Dimitrios (författare)
Natl & Capodistrian Univ Athens, Dept Cardiol 2, Attikon Univ Hosp, Athens, Greece.
Gurbel, Paul A. (författare)
Inova Heart & Vasc Inst, Inova Ctr Thrombosis Res & Drug Dev, Falls Church, VA USA.
Hochholzer, Willibald (författare)
Univ Heart Ctr Freiburg Bad Krozingen, Dept Cardiol & Angiol 2, Freiberg, Germany.
De Luca, Leonardo (författare)
San Giovanni Evangelista Hosp, Lab Intervent Cardiol, Div Cardiol, Tivoli Rome, Italy.;Mediterranean Acad Assoc Res & Studies Cardiol, Marseille, France.;Aix Marseille Univ, INSERM, UMRS 1076, Marseille, France.
Bonello, Laurent (författare)
Hop Nord Marseille, AP HP, Dept Cardiol, Marseille, France.
Aradi, Daniel (författare)
Heart Ctr Balatonfured, Budapest, Hungary.;Semmelweis Univ Budapest, Budapest, Hungary.
Cuisset, Thomas (författare)
CHU Timone, Dept Cardiol, Marseille, France.;Aix Marseille Univ, Fac Med, Marseille, France.
Tantry, Udaya S. (författare)
Inova Heart & Vasc Inst, Inova Ctr Thrombosis Res & Drug Dev, Falls Church, VA USA.
Wang, Tracy Y. (författare)
Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
Valgimigli, Marco (författare)
Bern Univ Hosp, Swiss Cardiovasc Ctr Bern, Bern, Switzerland.
Waksman, Ron (författare)
MedStar Washington Hosp Ctr, Sect Intervent Cardiol, Washington, DC USA.
Mehran, Roxana (författare)
Icahn Sch Med Mt Sinai, New York, NY USA.
Montalescot, Gilles (författare)
Sorbonne Univ Paris 6, Hop Pitie Salpetriere, ACTION Study Grp, Paris, France.
Franchi, Francesco (författare)
Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA.
Price, Matthew J. (författare)
Scripps Clin, Div Cardiovasc Dis, La Jolla, CA USA.
visa färre...
Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England. (creator_code:org_t)
LIPPINCOTT WILLIAMS & WILKINS, 2017
2017
Engelska.
Ingår i: Circulation. - : LIPPINCOTT WILLIAMS & WILKINS. - 0009-7322 .- 1524-4539. ; 136:20, s. 1955-
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Dual antiplatelet therapy with aspirin and a P2Y(12) inhibitor is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes and for those undergoing percutaneous coronary interventions. The availability of different oral P2Y(12) inhibitors (clopidogrel, prasugrel, ticagrelor) has enabled physicians to contemplate switching among therapies because of specific clinical scenarios. The recent introduction of an intravenous P2Y(12) inhibitor (cangrelor) further adds to the multitude of modalities and settings in which switching therapies may occur. In clinical practice, it is not uncommon to switch P2Y(12) inhibitor, and switching may be attributed to a variety of factors. However, concerns about the safety of switching between these agents have emerged. Practice guidelines have not fully elaborated on how to switch therapies, leaving clinicians with limited guidance on when and how to switch therapies when needed. This prompted the development of this expert consensus document by key leaders from North America and Europe with expertise in basic, translational, and clinical sciences in the field of antiplatelet therapy. This expert consensus provides an overview of the pharmacology of P2Y(12) inhibitors, different modalities and definitions of switching, and available literature and recommendations for switching between P2Y(12) inhibitors.

Ämnesord

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

drug interactions
hemorrhage
pharmacodynamics
platelet aggregation inhibitors
P2Y(12) receptor inhibitors
thrombosis

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy